Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 224-236

  Leftheris, Katerina ^a   Kline, Toni ^a   Vite, Gregory D ^a   Cho, Young H ^a   Bhide, Rajeev S ^a   Patel, Dinesh V ^a   Patel, Manorama M ^a   Schmidt, Robert J ^a   Weller, Harold N ^a   Andahazy, Mary L ^a   Carboni, Joan M ^a   Gullo Brown, Johnni L ^a   Lee, Francis Y F ^a   Ricca, Carol ^a   Rose, William C ^a   Yan, Ning ^a   Barbacid, Mariano ^a   Hunt, John T ^a   Meyers, Chester A ^a   Seizinger, Bernd R ^a   Zahler, Robert ^a   Manne, Veeraswamy ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; N [[2 [N (2 AMINO 3 MERCAPTOPROPYL) TERT LEUCYL] 1,2,3,4 TETRAHYDRO 3 ISOQUINOLINYL]CARBONYL]GLUTAMINE; N [[2 [N (2 AMINO 3 MERCAPTOPROPYL) TERT LEUCYL] 1,2,3,4 TETRAHYDRO 3 ISOQUINOLINYL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; ENZYME INHIBITORS; GENES, RAS; GLUTAMATES; ISOQUINOLINES; METHIONINE; MICE; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEIN P21(RAS); PROTEIN ISOPRENYLATION; RATS; SWINE; TETRAHYDROISOQUINOLINES; TRANSFECTION; TRANSFERASES; TUMOR CELLS, CULTURED; VALINE;

EID: 13344276587     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950642a     Document Type: Article

References (33)

1. Barbacid, M. In Annual Review of Biochemistry; Richardson, C., Ed.; Annual Reviews Inc.: Palo Alto, CA, 1987; Vol. 56, pp 779-827.
2. Kato, K.; Cox, A. D.; Hisaka, M. M.; Graham, S. M.; Buss, J. E.; Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6403-6407.
3. Jackson, J. H.; Cochrane, C. G.; Bourne, J. R.; Solski, P. A.; Buss, J. E.; Der, C. J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 3042-3046.
4. Gibbs, J. B. Ras C-Terminal Processing Enzymes-New Drug Targets? Cell 1991, 65, 1-4.
5. Gutierrez, L.; Magee, A. I.; Marshall, C. J.; Hancock, J. F. Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J. 1989, 8, 1093-1098.
6. Newman, C. M.; Magee, A. I. Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochim. Biophys. Acta 1993, 1155, 79-96.
7. Schafer, W. R.; Rine, J. Protein prenylation: Genes, Enzymes, Targets and Functions. Annu. Rev. Genet. 1992, 26, 209-237.
8. Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. All Ras Proteins Are Polyisoprenylated but Only Some are Palmitoylated. Cell 1989, 57, 1167-1177.
9. Garcia, A. M.; Rowell, C.; Ackermann, K.; Kowalczyk, J. J.; Lewis, M. D. Peptidomimetic Inhibitors of Ras Farnesylation and Function in Whole Cells. J. Biol. Chem. 1993, 268, 18415-18418.
10. Marsters, J. C.; McDowell, R. S.; Reynolds, M. E.; Oare, D. A.; Somers, T. C.; Stanley, M. S.; Rawson, T. E.; Struble, M. E.; Burdick, D. J.; Chan, K. S.; Duarte, C. M.; Paris, K. J.; Tom, J. Y. K.; Wan, D. T.; Xue, Y.; Burnier, J. P. Benzodiazepine Peptidomimetic Inhibitors of Farnesyltransferase. Bioorg. Med. Chem. 1994, 2, 949-957.
11. Graham, S. L.; deSolms, S. J.; Giuliani, E. A.; Kohl, N. E.; Josser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deana, A. A.; Garsky, V. M.; Scholz, T. H.; Gibbs, J. B.; Smith, R. L. Pseudopeptide Inhibitors of Ras Farnesyl-Protein Transferase. J. Med. Chem. 1994, 37, 725-732.
12. 2X Motif. Bioorg. Med. Chem. Lett. 1994, 4, 887-892.
13. Harrington, E. M.; Kowalczyk, J. J.; Pinnow, S. L.; Ackermann, K.; Garcia, A. M.; Lewis, M. D. Cysteine and Methionine Linked by Carbon Pseudopeptides Inhibit Farnesyl Transferase. Bioorg. Med. Chem. Lett. 1994, 4, 2775-2780.
14. Manne, V.; Ricca, C. S.; Brown, J. G.; Tuomari, A. V.; Yan, N.; Patel, D. V.; Schmidt, R.; Lynch, M. J.; Ciosek, J.; Carboni, J. M.; Robinson, S.; Gordon, E. M.; Barbacid, M.; Seizinger, B. R.; Biller, S. A. Ras Farnesylation as a Target for Novel Antitumor Agents: Potent and Selective Farnesyl Diphosphate Analog Inhibitors of Farnesyltransferase. Drug Dev. Res. 1995, 34, 121-137.
15. Manne, V.; Yan, N.; Carboni, J. M.; Tuomari, A. V.; Ricca, C. S.; Brown, J. G.; Andahazy, M. L.; Schmidt, R. J.; Patel, D.; Zahler, R.; Weinmann, R.; Der, C. J.; Cox, A. D.; Hunt, J. T.; Gordon, E. M.; Barbacid, M.; Seizinger, B. R. Bisubstrate Inhibitors of Farnesyltransferase: A Novel Class of Specific Inhibitors of Ras Transformed Cells. Oncogene 1995, 10, 1763-1779. Patel, D. V.; Gordon, E. M.; Schmidt, R. J.; Weller, H. N.; Young, M. G.; Zahler, R.; Barbacid, M.; Carboni, J. M.; Gullo-Brown, J. L.; Hunihan, L.; Ricca, C.; Robinson, S.; Seizinger, B. R.; Toumari, A. V.; Manne, V. Phosphinyl Acid- Based Bisubstrate Analog Inhibitors of Ras Farnesyl Protein Transferase. J. Med. Chem. 1995, 58, 435-442.
16. Manne, V.; Yan, N.; Carboni, J. M.; Tuomari, A. V.; Ricca, C. S.; Brown, J. G.; Andahazy, M. L.; Schmidt, R. J.; Patel, D.; Zahler, R.; Weinmann, R.; Der, C. J.; Cox, A. D.; Hunt, J. T.; Gordon, E. M.; Barbacid, M.; Seizinger, B. R. Bisubstrate Inhibitors of Farnesyltransferase: A Novel Class of Specific Inhibitors of Ras Transformed Cells. Oncogene 1995, 10, 1763-1779. Patel, D. V.; Gordon, E. M.; Schmidt, R. J.; Weller, H. N.; Young, M. G.; Zahler, R.; Barbacid, M.; Carboni, J. M.; Gullo-Brown, J. L.; Hunihan, L.; Ricca, C.; Robinson, S.; Seizinger, B. R.; Toumari, A. V.; Manne, V. Phosphinyl Acid- Based Bisubstrate Analog Inhibitors of Ras Farnesyl Protein Transferase. J. Med. Chem. 1995, 58, 435-442.
17. Vogt, A.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Hamilton, A. D.; Sebti, S. M. A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing. J. Biol. Chem. 1995, 270, 660-664.
18. ras Farnesyltransferase. J. Biol. Chem. 1994, 269, 12410-12413.
19. Clerc, F. F.; Guitton, J. L.; Fromage, M.; Lelievre, Y.; Duchesne, M.; Tocque, B.; James-Surcouf, E.; Commercon, A.; Becauart, J. Constrained Analogs of KCVFM With Improved Inhibitory Properties Against Farnesyl Transferase. Bioorg. Med. Chem. Lett. 1995, 1779-1784.
20. Goldstein, J. L.; Brown, M. S.; Stradley, S. J.; Reiss, Y.; Gierasch, L. M. Nonfarnesylated Tetrapeptide Inhibitors of Protein Farnesyltransferase. J. Biol. Chem. 1991, 266, 15575-15578.
21. Kohl, N. E.; Mosser, S- D.; deSolms, S. J.; Giulani, E. A.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.; Oliff, A.; Gibbs, J. B. Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor. Science 1993, 260, 1934-1937.
22. Pinder, R. M.; Butcher, B. H.; Buxton, D. A.; Howells, D. J. 2-Aminoindan-2-carboxylic acids. Potential Tyrosine Hydroxylase Inhibitors. J. Med. Chem. 1971, 14, 892-893.
23. Kaur, P.; Uma, K.; Balaram, P.; Chauhan, V. S. Synthetic and conformational studies on dehydrophenylalanine containing model peptides. Int. J. Pep. Prot. Res. 1989, 33, 103-109.
24. Fehrentz, J. A.; Heitz, A.; Castro, B. Synthesis of aldehydic peptides inhibiting renin Int. J. Pept. Protein Res. 1985, 26, 236-241.
25. Leete, E.; Mueller, M. E. Biomimetic Synthesis of Anatabine from 2,5-Dihydropyridine Produced by the Oxidative Decarboxylation of Baikiain. J. Am. Chem. Soc. 1982, 104, 6440-6444.
26. Manne, V.; Roberts, D.; Tobin, A.; O'Rourke, E.; DeVirgilio, M.; Meyers, C. A.; Ahmed, N.; Kurz, B.; Resh, M.; Kung, H. F.; Barbacid, M. Identification and Preliminary Characterization of protein-cysteine farnesyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7541-7545.
27. Gelman, S. H. On the Role of Methionine Residues in the Sequence- Independent Recognition of Nonpolar Protein Surfaces. Biochemistry 1991, 30, 6633-6636.
28. Tucker, J.; Sczakiel, G.; Feuerstein, J.; John, J.; Goody, R. S.; Wittinghofer, A. Expression of p21 proteins in Escherichia coli and stereochemistry of the nucleotide-binding site. EMBO J. 1986, 5, 1351-1358.
29. Cox, A. D.; Der, C. The ras/cholesterol connection: Implications for ras oncogenicity. Crit. Rev. Oncogenesis 1992, 3, 365-400.
30. Hatton, S.; Ulsh, L. S.; Halliday, K.; Shih, T. Y. Biochemical properties of a highly purified v-rasH p21 protein overproduced in Escherichia coli and inhibition of its activities by a monoclonal antibody. Mol. Cell. Biol. 1985, 5, 1449-1455.
31. Cox, A. D.; Hisaka, M. M.; Buss, J. E. Specific Isoproenoid Modification is required for function of normal, but not oncogenic ras function. Mol. Cell. Biol. 1992, 12, 2606-2615.
32. Sukumar, S.; Carney, W. P.; Barbacid, M. Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas. Science 1988, 240, 524-526.
33. Geran, R. I.; Greenberg, N. H.; MacDonald, M. M.; Schumacher, A. M.; Abbot, B. J. Protocols for screening chemical agents and natural products against animal tumor and other biological systems. Cancer Chemother. Rep. 1972, 3, 1-103.